成人择期围术期使用GLP-1受体激动剂、GIP激动剂及SGLT2抑制剂的跨学科共识声明
该跨学科共识由麻醉医师协会等机构制定,针对使用GLP-1受体激动剂、双重GIP受体激动剂或SGLT2抑制剂的成人择期手术患者,通过文献回顾和三轮改良Delphi流程形成推荐。共识建议前两类药术前继续使用并全面风险评估,SGLT2抑制剂术前一天及手术当天停药,强调共享决策。
要点
- GLP-1受体激动剂和双重GIP受体激动剂术前应继续使用,并全面风险评估。
- 使用SGLT2抑制剂者应在术前一天及手术当天停药。
- 所有患者应与共享决策方式讨论风险及缓解策略。
核心结论
- 对于使用GLP-1受体激动剂和双重GIP受体激动剂的择期手术成人,建议术前继续用药并全面风险评估。
- 使用SGLT2抑制剂者建议术前一天及手术当天停药。
- 所有患者应采用共享决策讨论围术期风险及缓解策略。
研究设计与样本
- 制定机构包括麻醉医师协会、英国临床糖尿病医师协会、英国肥胖与代谢外科学会等。
- 共识制定纳入外科医生、麻醉医生、内科医生、药师及相关经验人士。
- 采用定向文献回顾和三 round 改良Delphi流程生成并批准推荐。
主要发现
- GLP-1受体激动剂、双重GIP受体激动剂和SGLT2抑制剂在围术期患者中使用日益增加。
- 这些药物可能与围术期肺误吸或正常血糖酮酸中毒风险相关。
关键数值与推荐
- 使用GLP-1受体激动剂和双重GIP受体激动剂者:术前继续用药;全面风险评估和分层;接受可能减轻肺误吸风险的围术期技术(镇静或全麻前、中、后)。
- 使用SGLT2抑制剂者:术前一天及手术当天停药。
- 所有患者:以共享决策方式讨论风险和缓解策略。
临床怎么用
- 麻醉科医生应识别使用这三类药物的择期手术患者并按共识管理。
- 对GLP-1受体激动剂和双重GIP受体激动剂使用者,术前不擅自停药,加强风险评估和误吸预防。
- 对SGLT2抑制剂使用者,确认术前一天及手术当天停药。
- 与患者共同决策,讨论围术期风险及缓解策略。
局限性
- 共识基于现有有限证据,需更多研究证据支持。
- 共识为实用性声明,旨在支持共享决策和改善安全。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Glucagon-like peptide-1 receptor agonists, dual glucose-dependent insulinotropic peptide receptor agonists and sodium-glucose cotransporter-2 inhibitors are used increasingly in patients receiving peri-operative care. These drugs may be associated with risks of peri-operative pulmonary aspiration or euglycaemic ketoacidosis. We produced a consensus statement for the peri-operative management of adults taking these drugs. METHODS: This multidisciplinary consensus statement included surgeons, anaesthetists, physicians, pharmacists and people with lived experience relevant to these guidelines. Following the directed literature review, a three-round modified Delphi process was conducted to generate and ratify recommendations. RESULTS: Patients taking glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic peptide receptor agonists should: continue these drugs before surgery; have full risk assessment and stratification; and receive peri-operative techniques that may mitigate risk of pulmonary aspiration before, during and after sedation or general anaesthesia. Patients taking sodium-glucose cotransporter-2 inhibitors should omit them the day before and the day of a procedure. All patients should have risks and mitigation strategies discussed with a shared decision-making approach. DISCUSSION: Until more evidence becomes available, this pragmatic, multidisciplinary consensus statement aims to support shared decision-making and improve safety for patients taking glucagon-like peptide-1 receptor agonists, dual glucose-dependent insulinotropic peptide receptor agonists and sodium-glucose cotransporter-2 inhibitors during the peri-operative period.
引用
- El-Boghdadly K, Dhesi J, Fabb P, et al. Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association. Anaesthesia. 2025. PMID: 39781571. doi:10.1111/anae.16541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。